ጦTwS
[Abstract]:Objective to observe the effect of ectini on experimental hepatic fibrosis in rats with dimethylnitrosamine (DMN). Methods 48 male Wistar rats were randomly divided into normal group (n = 10), model group (n = 14), control group (n = 12) and Eketinib group (n = 12). Model group, Fuzheng Huayu group and Eketinib group were injected intraperitoneally with DMN 10 μ g kg-1 for 3 days a week for 4 weeks. Since the 3rd week of model making, Fuzheng Huayu group and Eketinib group were given 4. 0 g kg-1, Eketini 5 mg kg-1 by gavage, 7 days a week, respectively, in Fuzheng Huayu group and Eketini group. HE staining and collagen staining were used to observe liver inflammation and collagen deposition. Serum liver function and hydroxyproline (HYP) were detected by Jamall method. The expression of -smooth muscle actin (-SMA) and transforming growth factor-β (TGF- β) in liver tissue was detected by fluorescence quantitative PCR. Results the incidence of ascites, the content of serum total bilirubin (T.Bil), the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and the content of HYP in liver tissue in the model group were significantly higher than those in the normal group (P0.01). The content of serum albumin (Alb) decreased significantly, the inflammation of liver tissue and collagen deposition aggravated (P0.01), and the expression of -SMA and TGF- β m RNA in liver tissue increased (P0.05). Eketinine significantly reduced the incidence of ascites, decreased the level of ALT,AST,T.Bil and HYP in liver tissue (P0.05), and alleviated inflammation and collagen deposition in liver tissue (P0.05). The expression of -SMA and TGF- β m RNA in liver tissue was down-regulated (P0.05). Conclusion Eketinib can improve experimental hepatic fibrosis induced by DMN in rats.
߆λ Ϻt(y)ˎWt(y)Ժβо;ϺУt(y)(ni)ƌWE-оԺ;Ϻt(y)Rc;ICc;
𡿣ҿƼش(2014ZX10005001) Ϻt(y)WI(lng)܊˲Ӌ(LJ10005)
̖R575.2
īI
P(gun)ڿՓ ǰ3l
1 S;ƽ;;;w܊;xt;;΅茦DMNwSνMTIMP-1_Ӱ[J];ЇˎcRs־;200701
2 ;ɺ;ꐈ@;GG;;ꐸ߷;;һNĶwSģT䲡c[J];ЇW;200702
3 ;ӡ;;x;r;ɺ;S;κh;ƽ;;BeagleȮδκͷ(f)ڷ}Ķ[J];ЇˎWcWs־;201303
īI
P(gun)ڿՓ ǰ10l
1 ÷;÷;ɺ;ž;m;;һԴ´wSģиǠIJ׃[J];øKs־;200904
2 κ;;;T;L;ƽ;ُ;G;SG;;΅R(yng)оMչ[J];t(y)ˎ;201110
3 ;ָͥ;w;ï;;Һ˅g(sh)wS^I-Ѫܾoϵy(tng)Ӱ[J];At(y)ˎs־;201304
4 Chun Gao;Long Fang;Hong-Chuan Zhao;Jing-Tao Li;Shu-Kun Yao;;Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma:a cross-sectional case-control study from Chinese patients with HBV infection[J];Hepatobiliary & Pancreatic Diseases International;201304
5 German G.Gomez;Jill Wykosky;Ciro Zanca;Frank B.Furnari;Webster K.Cavenee;;Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks[J];Cancer Biology & Medicine;201304
6 Wen Xie;Hong Zhao;Yu Chen;Qin Zhang;Wei Lu;Wei Liu;Ai-rong Hu;Han-wei Li;Ping Feng;Ming-sheng Chen;Cun-jin Mei;Xiao-lin Guo;Xiao-hu Zhao;Jiang-bin Wang;Zheng-qin Fan;Jian-he Gan;Qing Xie;Jun Cheng;;A Retrospective,Multi-Center,Post-Marketing Observational Study to Evaluate the Effectiveness of Ademetionine 1,4-Butanedisulfonate Injection(Transmetil~)Treatment in Chinese Patients with Intrahepatic Cholestasis Caused by Viral Hepatitis[J];Infection International(Electronic Edition);201302
7 ӭ;Сt;Ɩ|;ξw;;{(dio)C/EBPPAR1HSC-T6Ӱ[J];ؑct(y)W;201336
8 ;;O;;ɼڸwSе{(dio)[J];t(y)W;201403
9 Ƽʮش(lin)n}M;;ײP(gun)ӲR\uͿίľCϹ[J];øKs־;201402
10 ;;;ͤf;̫;;;Ӳθ늻Ɂyͼl(f)ԭ̽[J];Ft(y)WԺW;201402
P(gun)ʿWλՓ ǰ10l
1 ;DMNСΓpģ͵ĽˎoЧur[D];Vt(y)ˎW;2008
2 S;ɐحh(hun)ϩՌKǰ׃oCƵČо[D];߅W;2012
3 Ƽ;(ni)ԴԴanandamidexѿԭѪxwSСw(ni)/Ӱ푵ij̽ӑ[D];AпƼW;2013
4 ܼtG;θER-36cEGFR̖ͨ·о[D];AпƼW;2013
5 ;(lin)ݽ錧CTGF˹microRNAwSо[D];܊t(y)W;2013
6 R;B(ti)Ǡcΰg|(zh)ѪɵP(gun)о[D];ɽW;2013
7 ;Hedgehog̖ͨ·ڸwSСģеüˎA(y)̽[D];f(xi)t(y)WԺ;2013
8 ܊;miR-143ٰD(zhun)ƼCƵijо[D];ϴW;2013
9 ;HAb18G/CD147MwSl(f)üәCо[D];܊t(y)W;2013
10 ;g|(zh)ɼѪɼw(ni)ʾۙMΓpޏ(f)Čо[D];܊t(y)W;2013
P(gun)TʿWλՓ ǰ10l
1 ;g(sh)wίذl(f)Էg|(zh)wSRЧо[D];Їt(y)ƌWԺ;2011
2 ꐻؑ;΅SָyDVо[D];㽭W;2012
3 ʯ;wSСνMIGFBPrP1TGF1/Smad̖ͨ·ĄӑB(ti)׃P(gun)о[D];ɽt(y)ƴW;2009
4 Rƽ;ˎСĻWɷֺо[D];t(y)ˎW;2012
5 ¾V;ڷٰEGFRͻ׃zyЧ^[D];Ϸt(y)ƴW;2012
6 ˇ;utSɫAԴwSγɵӰ푼Cо[D];It(y)WԺ;2011
7 n;οcŻ(lin)Ì[ąf(xi)ͬЧ(yng)Čо[D];ɽt(y)ƴW;2013
8 o;zA{(dio)EGFRֳٰD(zhun)ƵӰ[D];ӱt(y)ƴW;2013
9 ;ERٰPAX-2AIB-1HER-2_{(dio)ؙCƵо[D];ӱt(y)ƴW;2013
10 ꐷ;(ni)،Ǡ_Y(ji)MLӵӰ[D];ɽt(y)ƴW;2013
īI
P(gun)ڿՓ ǰ10l
1 Ԋ,d;t(y)ˎwSоr[J];ЇᎧt(y)W;200502
2 xP,ƽ,,D,,ɺ,;ȡCCl_4DMNTĴwSӰ[J];Ϻt(y)ˎs־;199910
3 GG,ɺ;仯WɷֿwSÙCоMչ[J];t(y)Y(ji)όW;200402
4 ԙ,xP,ɺ,ƽ,Ԫ;B}TĸwSKD(zhun)LӦ1wױ_Ӱ[J];t(y)Y(ji)όW;200504
5 ;ɺ;⸣;Ļ;ƽ;;wSγиθ]ڌճBzԭ׃[J];As־;200103
6 Ļ;ƽ;⸣;;l(wi);LA;ɺ;;֬|(zh)^ڶwSγ^е[J];As־;200106
7 ƽ,A;wSģ͵Ľ[J];As־;200206
8 t;ScwSо[J];t(y)WC;200405
9 ,wB;wSČģ[J];ЇW;200404
10 ;ǠcwS[J];AKs־;200004
īI
P(gun)ڿՓ ǰ4l
1 ɺ,Ļ,ƽ,,xP,;´֬|(zh)^׃cˎA(y)[J];AKs־;2001S1
2 ;h;ν;V;;ڶTСΓpģ[--1µĄӑB(ti)_[J];Їt(y)Y(ji)s־;201004
3 ǽ,,ɘs,fǧt,;ԸģIL-18Fas mRNAĄӑB(ti)׃[J];Kt(y)ˎ;200312
4 ;[J];;
ľ̖2402314
朽ӣhttp://www.lk138.cn/yixuelunwen/xiaohjib/2402314.html